Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP14 | P50281 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PYGL | P06737 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27821171 | 1.00 | REN (0.39) | RENCTSSCTSKMMP1MMP9 | |
| SCHEMBL1251753 | 0.82 | KMT2A (0.49) | RENCTSSCTSKKMT2AHDAC4 | |
| SCHEMBL28024551 | 0.82 | KMT2A (0.49) | RENCTSSCTSKKMT2AHDAC4 | |
| SCHEMBL1251750 | 0.82 | KMT2A (0.49) | RENCTSSCTSKKMT2AHDAC4 | |
| SCHEMBL1163035 | 0.79 | MMP13 (0.35) | CTSSCTSKMMP1MMP9KMT2A | |
| SCHEMBL5090525 | 0.79 | MME (0.39) | CTSSCTSKKMT2ALTA4HGAA | |
| SCHEMBL23005710 | 0.76 | CTSS (0.47) | RENCTSSCTSKMMP1KMT2A | |
| SCHEMBL22125910 | 0.76 | CTSS (0.47) | RENCTSSCTSKMMP1KMT2A | |
| SCHEMBL22285128 | 0.76 | CTSS (0.47) | RENCTSSCTSKMMP1KMT2A | |
| SCHEMBL22285129 | 0.76 | CTSS (0.47) | RENCTSSCTSKMMP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2537846-B1 | Intermediate compounds for preparing SMAC peptidomimetics | NOVARTIS AG (CH) | 2015-09-16 | — | — | EP | disclosed |
| EP-2102229-B1 | PYRROLYDINE DERIVATIVES AS IAP INHIBITORS | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-20140004101-A1 | SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS | NOVARTIS AG (CH) | 2014-01-02 | — | — | US | disclosed |
| US-8552003-B2 | (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-4-(4-fluorobenzoyl)-thiazol-2-yl]pyrrolidin-1-yl}-2-oxoethyl)-2-methylamino-propionamide, or pharmaceutically acceptable salts thereof and their uses | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| US-8546336-B2 | SMAC peptidometics useful as IAP inhibitors | NOVARTIS AG (CH) | 2013-10-01 | — | — | US | disclosed |
| EP-2051990-B1 | SMAC PEPTIDOMIMETICS USEFUL AS IAP INHIBITORS | NOVARTIS AG (CH) | 2013-02-06 | — | — | EP | disclosed |
| US-20130005663-A1 | SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS | NOVARTIS AG (CH) | 2013-01-03 | — | — | US | disclosed |
| EP-2537850-A1 | Organic compounds | Novartis AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| EP-2537846-A1 | Organic compounds | Novartis AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-8044209-B2 | Pyrrolydine derivatives as IAP inhibitors | NOVARTIS AG (CH) | 2011-10-25 | — | — | US | disclosed |
| US-20110065726-A1 | Organic Compounds | NORVARTIS AG | 2011-03-17 | — | — | US | disclosed |
| US-20110015232-A1 | Pyrrolydine Derivatives as IAP Inhibitors | NOVARTIS AG | 2011-01-20 | — | — | US | disclosed |
| EP-2102229-A1 | PYRROLYDINE DERIVATIVES AS IAP INHIBITORS | Novartis AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008045905-A1 | PYRROLYDINE DERIVATIVES AS IAP INHIBITORS | NOVARTIS AG (CH) | 2008-04-17 | — | — | WO | disclosed |
| WO-2006107963-A2 | PROCESS FOR PREPARING DIPEPTIDE AMIDES | NOVARTIS AG (CH) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065726-A1 | Organic Compounds | VHL, SLCO2B1, SLCO2A1 | REN 709/4885CTSS 2553/4885CTSK 3178/4885 |
| US-20130005663-A1 | SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS | BIRC5, BIRC2, BIRC7 | REN 2867/4885CTSS 2909/4885CTSK 2921/4885 |
| US-20140004101-A1 | SMAC PEPTIDOMETICS USEFUL AS IAP INHIBITORS | BIRC5, BIRC2, BIRC7 | REN 2867/4885CTSS 2909/4885CTSK 2921/4885 |
| US-20110015232-A1 | Pyrrolydine Derivatives as IAP Inhibitors | XIAP, BIRC5, BIRC3 | REN 2137/4885CTSS 1851/4885CTSK 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.